Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial

JAMA Oncology

Volumn 3, Issue 1, 2017, Pages E1-E9

  Szlosarek, Peter W ^a   Steele, Jeremy P ^a   Nolan, Luke ^a   Gilligan, David ^a   Taylor, Paul ^a   Spicer, James ^a   Lind, Michael ^a   Mitra, Sankhasuvra ^a   Shamash, Jonathan ^a   Phillips, Melissa M ^a   Luong, Phuong ^a   Payne, Sarah ^a   Hillman, Paul ^a   Ellis, Stephen ^a   Szyszko, Teresa ^a   Dancey, Gairin ^a   Butcher, Lee ^a   Beck, Stephan ^a   Avril, Norbert E ^a   Thomson, Jim ^a   Johnston, Amanda ^a   Tomsa, Marianne ^a   Lawrence, Cheryl ^a   Schmid, Peter ^a   Crook, Timothy ^a   Wu, Bor Wen ^a   Bomalaski, John S ^a   Lemoine, Nicholas ^a   Sheaff, Michael T ^a   Rudd, Robin M ^a   Fennell, Dean ^a   Hackshaw, Allan ^a   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017339834     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.100l/jamaoncd.2016.3049     Document Type: Article

References (34)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15): 1591-1603.
2. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol.2012;227(1):44-58.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644.
4. van Meerbeeck JP, Gaafar R, Manegold C, et al; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881-6889.
5. Nowak AK. Chemotherapy for malignant pleural mesothelioma: A review of current management and a look to the future. Ann Cardiothorac Surg. 2012;1(4):508-515.
6. Szlosarek PW, Klabatsa A, Pallaska A, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res. 2006;12(23):7126-7131.
7. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem. 2003;270(9):1887-1899.
8. Delage B, Fenneil DA, Nicholson L, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126(12):2762-2772.
9. Huang HY, Wu WR, Wang YH.et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: Aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;19(11):2861-2872.
10. Rabinovich S, Adler L, Yizhak K. et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature. 2015;527(7578): 379-383.
11. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20.000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 2002;62(19):5443-5450.
12. Cheng PN, Lam TL, Lam WM, et al. Pegylated recombinant human arginase (rhArg- peg5, 000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67(1): 309-317.
13. Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase l/ll studies. J din Oncol. 2004, 22(10): 1815-1822.
14. Ascierto PA, Scala S, Castello G, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J din Oncol. 2005;23(30):7660-7668.
15. Glazer ES, Piccirillo M, Albino V, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J din Oncol. 2010;28(13):2220-2226.
16. Yang TS, Lu SN, Chao Y, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer. 2010;103(7): 954-960.
17. Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: A method for identifying cancers sensitive to arginine deprivation. Cancer. 2004;100(4):826-833.
18. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257-260.
19. Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation. Cancer. 2004, 101 (3):587-595.
20. Dedeurwaer der S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium Methylation 450K technology. Epigenomics. 2011;3(6):771-784.
21. Morris TJ, Butcher LM, Feber A, et al. ChAMP: 450k Chip Analysis Methylation Pipeline. Bioinformatics. 2014, 30(3):428-430.
22. Young H, Baum R, Cremerius U, et al; European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Measurement of clinical and subclinical tumour response using ['8F]-fluorodeoxyglucoseand positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35(13): 1773-1782.
23. Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J din Oncol. 2006; 24(28):4587-4593.
24. Royston P, Parmar MIC. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011; 30(19):2409-2421.
25. Schnipper LE, Davidson NE, Wollins DS, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23): 2563-2577.
26. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236-1242.
27. Kobayashi E, Masuda M, Nakayama R, et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. MolCancer Ther. 2010;9(3):535-544.
28. Allen MD, Luong P, Hudson C, et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res. 2014;74 (3):896-907.
29. Ott PA, Carvajal RD, Pandit-Taskar N, et al. Phase l/ll study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs. 2013;31(2):425-434.
30. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1a/Sp4. Mol Cancer Ther. 2009;8(12): 3223-3233.
31. Feun LG, Marini A, Walker G, et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer. 2012;106(9): 1481-1485.
32. Battisti S, Valente D, Albonici L, Bei R, Modesti A, Palumbo C. Nutritional stress and arginine auxotrophy confer high sensitivity to chloroquine toxicity in mesothelioma cells. Am J Respir Cell Mol Biol. 2012;46(4):498-506.
33. Szlosarek PW. Arginine deprivation and autophagic cell death in cancer. Proc Natl Acad Sci U SA. 2014;111(39):14015-14016.
34. Pacey S, Spicer JF, Chan PY, et al. A phase 1 study in patients with mesothelioma or non small cell lung tumours requiring arginine to assess ADI-PEG 20 with pemetrexed and cisplatin (TRAP study). Paper presented at: Molecular Targets and Cancer Therapeutics, November 5-9, 2015; Boston, MA. Abstract B23.